These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 29966520)
1. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. Afzal MZ; Mercado RR; Shirai K J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520 [TBL] [Abstract][Full Text] [Related]
2. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study. Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991 [TBL] [Abstract][Full Text] [Related]
3. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347 [TBL] [Abstract][Full Text] [Related]
4. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663 [TBL] [Abstract][Full Text] [Related]
6. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. Moya-Plana A; Herrera Gómez RG; Rossoni C; Dercle L; Ammari S; Girault I; Roy S; Scoazec JY; Vagner S; Janot F; Eggermont AMM; Robert C Cancer Immunol Immunother; 2019 Jul; 68(7):1171-1178. PubMed ID: 31172258 [TBL] [Abstract][Full Text] [Related]
8. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333 [TBL] [Abstract][Full Text] [Related]
9. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816 [TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
11. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. Naik GS; Buchbinder EI; Cohen JV; Manos MP; Johnson AEW; Bowling P; Aizer AA; Schoenfeld JD; Lawrence DP; Haq R; Hodi FS; Sullivan RJ; Ott PA J Immunother; 2021 Oct; 44(8):307-318. PubMed ID: 34406158 [TBL] [Abstract][Full Text] [Related]
12. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center. Afzal MZ; Shirai K Melanoma Res; 2018 Aug; 28(4):341-347. PubMed ID: 29750753 [TBL] [Abstract][Full Text] [Related]
16. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819 [TBL] [Abstract][Full Text] [Related]
17. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. Wang LX; Quach HT; Moodabigil NV; Davis EJ; Sosman JA; Dusetzina SB; Johnson DB Cancer; 2020 Jan; 126(2):322-328. PubMed ID: 31580492 [TBL] [Abstract][Full Text] [Related]
18. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. Afzal MZ; Mabaera R; Shirai K J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. Jensen C; Madsen DH; Hansen M; Schmidt H; Svane IM; Karsdal MA; Willumsen N J Immunother Cancer; 2018 Dec; 6(1):152. PubMed ID: 30567561 [TBL] [Abstract][Full Text] [Related]